A detailed history of Shell Asset Management CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Shell Asset Management CO holds 14,578 shares of VRTX stock, worth $6.57 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
14,578
Previous 16,074 9.31%
Holding current value
$6.57 Million
Previous $7.53 Million 10.01%
% of portfolio
0.3%
Previous 0.34%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$460.0 - $505.78 $688,160 - $756,646
-1,496 Reduced 9.31%
14,578 $6.78 Million
Q1 2024

Jul 31, 2024

SELL
$407.69 - $446.08 $565,873 - $619,159
-1,388 Reduced 7.95%
16,074 $7.53 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $534,481 - $584,810
1,311 Added 8.12%
17,462 $7.3 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $966,231 - $1.16 Million
-2,817 Reduced 14.85%
16,151 $6.57 Million
Q3 2023

Nov 08, 2023

SELL
$338.18 - $362.46 $71,694 - $76,841
-212 Reduced 1.11%
18,968 $6.6 Million
Q2 2023

Jul 28, 2023

BUY
$314.42 - $351.91 $288,951 - $323,405
919 Added 5.03%
19,180 $6.75 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $11,612 - $13,247
-41 Reduced 0.22%
18,261 $5.75 Million
Q4 2022

Feb 07, 2023

SELL
$285.76 - $321.48 $1.58 Million - $1.78 Million
-5,523 Reduced 23.18%
18,302 $5.29 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $1.47 Million - $1.64 Million
-5,375 Reduced 18.41%
23,825 $6.9 Million
Q2 2022

Aug 09, 2022

SELL
$234.96 - $292.55 $897,782 - $1.12 Million
-3,821 Reduced 11.57%
29,200 $8.23 Million
Q1 2022

May 04, 2022

BUY
$221.42 - $260.97 $925,978 - $1.09 Million
4,182 Added 14.5%
33,021 $8.62 Million
Q4 2021

Feb 09, 2022

SELL
$177.01 - $223.45 $1.42 Million - $1.79 Million
-8,012 Reduced 21.74%
28,839 $6.33 Million
Q3 2021

Nov 04, 2021

SELL
$181.39 - $202.99 $3.23 Million - $3.61 Million
-17,808 Reduced 32.58%
36,851 $6.68 Million
Q2 2021

Aug 12, 2021

SELL
$187.49 - $221.1 $1.45 Million - $1.7 Million
-7,709 Reduced 12.36%
54,659 $11 Million
Q1 2021

May 10, 2021

SELL
$207.02 - $241.31 $3.09 Million - $3.6 Million
-14,921 Reduced 19.31%
62,368 $13.4 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $5.25 Million - $7 Million
25,367 Added 48.86%
77,289 $18.3 Million
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $82,319 - $97,598
-322 Reduced 0.62%
51,922 $14.1 Million
Q2 2020

Aug 10, 2020

BUY
$225.48 - $295.8 $8.13 Million - $10.7 Million
36,049 Added 222.59%
52,244 $15.2 Million
Q1 2020

May 11, 2020

SELL
$199.77 - $247.81 $361,783 - $448,783
-1,811 Reduced 10.06%
16,195 $3.85 Million
Q4 2019

Feb 13, 2020

SELL
$166.71 - $223.91 $84,521 - $113,522
-507 Reduced 2.74%
18,006 $3.94 Million
Q3 2019

Nov 12, 2019

SELL
$166.23 - $187.09 $405,268 - $456,125
-2,438 Reduced 11.64%
18,513 $3.14 Million
Q2 2019

Aug 12, 2019

BUY
$164.61 - $190.37 $158,684 - $183,516
964 Added 4.82%
20,951 $3.84 Million
Q1 2019

May 09, 2019

BUY
$163.73 - $194.7 $215,141 - $255,835
1,314 Added 7.04%
19,987 $3.68 Million
Q4 2018

Feb 13, 2019

SELL
$151.91 - $192.21 $768,664 - $972,582
-5,060 Reduced 21.32%
18,673 $3.09 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $178,967 - $205,653
-1,067 Reduced 4.3%
23,733 $4.57 Million
Q2 2018

Aug 10, 2018

BUY
$145.72 - $169.96 $192,787 - $224,857
1,323 Added 5.64%
24,800 $4.22 Million
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $182,981 - $213,795
-1,207 Reduced 4.89%
23,477 $3.83 Million
Q4 2017

Feb 09, 2018

BUY
$137.28 - $155.55 $431,333 - $488,738
3,142 Added 14.59%
24,684 $3.7 Million
Q3 2017

Oct 20, 2017

SELL
$148.13 - $162.24 $3.69 Million - $4.04 Million
-24,911 Reduced 53.63%
21,542 $3.28 Million
Q3 2017

Oct 18, 2017

BUY
$148.13 - $162.24 $6.88 Million - $7.54 Million
46,453
46,453 $5.22 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.